培美曲塞治疗老年晚期非小细胞肺癌疗效分析

目的观察培美曲塞单药二线治疗老年晚期非鳞癌NSCLC的疗效及毒性反应;方法经病理学或细胞学确诊的25例老年晚期NSCLC患者,均接受培美曲塞化疗,培美曲塞以500 mg/m2,第一天静脉滴注,21天为一周期,每例患者至少行2周期化疗;结果 CR 0例,PR 5例,SD 12例,PD 8例,有效率(RR)20.0%,临床获益率(CBR)68.0%。主要不良反应为骨髓抑制和胃肠道反应;结论培美曲塞治疗老年晚期NSCLC具有一定的疗效,毒性反应轻,耐受性好。

Curative effect analysis of pemetrexed in the treatment of elderly patients with non-small cell lung cancer at the advanced stage

Objective To observe the efficacy and toxicity of pemetrexed as second-line drug in the treatment of the elderly patients with advanced non-squamous and non-small cell lung cancer （NSCLC）. Methods 25 elderly patients with advanced NSCLC confirmed by pathology or cytology were treated with pemetrexed 500 mg/m2 through intravenous drip. 21 days was a cycle and each patient was given at least 2 cycles of chemotherapy. Results There was no ease of complete remission （ CR）, 5 cases of partial remission （ PR）, 12 cases of stable disease （SD） and 8 eases of progressive disease （PD） after the treatment. The overall response rate was 20.0% and the clinical beneficial rate was 68.0%. The major adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion Pemetrexed in the treatment of elderly patients with advanced NSCLC has a certain efficacy with mild toxicity and well tolerance.